Law360, New York (September 02, 2008) -- Purdue Pharma LP and generics maker Mallinckrodt Inc. have struck a deal that will allow Mallinckrodt to market and sell its cheaper version of the brand-name painkiller OxyContin for a licensing fee.
Putting to rest litigation in the U.S. District Court for the Southern District of New York, Mallinckrodt agreed to acknowledge that Purdue's patents for OxyContin are valid and enforceable. Purdue,...
